<p>(TheNewswire)</p>
<p>加拿大不列颠哥伦比亚省温哥华</p>
<p>– TheNewswire -</p>
<p>2026 年 3 月 19 日– MindBio</p>
<p>Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6);</p>
<p>(OTCQB:MBQIF)，(“公司” 或</p>
<p>“MindBio”) 是一家生物技术公司，专注于商业化基于人工智能的</p>
<p>语音分析技术，用于检测药物和酒精中毒，今天宣布</p>
<p>将其于 2026 年 2 月 18 日之前宣布的非承销私募融资（“融资”）</p>
<p>从 65 万美元增加至最高 150 万美元，依据该融资，公司计划</p>
<p>现在发行最多 2,500,000 个单位（“单位”），每个单位的价格为</p>
<p>0.60 美元，预计总收益最高可达 150 万美元。每个单位</p>
<p>将由一股普通股（每股为 “股份”）和一个股份购买权证（每个为 “权证”）组成。每个权证将赋予持有人在融资结束后三十六个月内以</p>
<p>0.80 美元的价格购买额外股份的权利，若在此期间内，加拿大证券交易所的股份收盘价超过 1.00 美元，权证将提前到期。</p>
<p>与融资完成相关，公司将向引荐订阅者的合格第三方支付介绍费。所有与融资相关发行的证券将根据适用的证券法，受到为期四个月零一天的转售限制。</p>
<p>融资的完成仍需最终的董事会和监管机构批准。</p>
<p>如需更多信息，请联系：</p>
<p>Justin Hanka，首席执行官</p>
<p>+61 433140886</p>
<p>justin@mindbiotherapeutics.com</p>
<p>www.mindbiotherapeutics.com</p>
<p>关于 MindBio Therapeutics Corp.</p>
<p>MindBio 是一家生物技术公司，专注于通过语音分析商业化人工智能预测技术，用于检测药物和酒精中毒。该人工智能预测模型使用超过 5000 万个数据点，仅通过人声就能以显著的准确性预测酒精中毒。公司正在开发一个企业平台，包括集成定制硬件和软件的边缘人工智能终端，用于在包括矿业、航空、建筑和执法等多个企业环境中，利用人声和人工智能检测药物和酒精中毒。</p>
<p>关于前瞻性声明的警示说明：</p>
<p>本新闻稿包含适用证券法意义上的 “前瞻性声明”，包括但不限于公司完成融资的能力。前瞻性声明可以通过诸如：“预期”、“打算”、“计划”、“预算”、“相信”、“项目”、“估计”、“期望”、“安排”、“预测”、“战略”、“未来”、“可能”、“可能”、“将要”、“可以”、“应该”、“会” 等词语及类似的未来时期的参考或否定或可比术语，以及通常用于未来和条件的术语来识别。前瞻性声明基于提供时的假设。然而，不能保证这些假设将反映这些项目或因素的实际结果。</p>
<p>此外，还有已知和未知的风险因素可能导致公司的实际结果和财务状况与前瞻性声明中所指示的有重大差异。因此，您不应依赖这些前瞻性声明。可能导致实际结果和财务状况与前瞻性声明中所指示的有重大差异的重要风险因素包括但不限于：公司可能无法筹集融资的总收益；未能获得最终监管批准；以及在其企业平台的开发或部署中面临技术挑战；加拿大和澳大利亚的一般经济、市场和商业条件；市场波动；以及本新闻稿中描述的任何交易或事件的时间表出现意外延误。所有前瞻性信息均完全受此警示声明的限制。</p>
<p>公司不承担修订或更新任何此类前瞻性声明的义务，也不承担公开宣布任何修订结果的义务，以反映未来的结果、事件或发展，除非法律要求。</p>
<p>加拿大证券交易所及其监管服务提供者（根据加拿大证券交易所政策定义的术语）对本发布的充分性或准确性不承担任何责任。</p>
<p>版权 (c) 2026 TheNewswire - 保留所有权利。</p>

IBBQ

纽交所高增长板生物技术指数 ETF - First Trust

2 倍做多纳斯达克生物技术 ETF - ProShares

<p>MindBio Therapeutics Corp. 宣布将其非承销私人配售的金额从 65 万美元增加至最高 150 万美元。该公司计划以每单位 0.60 美元的价格发行最多 250 万个单位，每个单位由一股普通股和一个认股权证组成。认股权证允许在 36 个月内以 0.80 美元的价格购买额外的股份。该发行需获得监管机构的批准，并将包括对符合条件的第三方的介绍费用。所有证券将有四个月的转售限制</p>

<p>(TheNewswire)</p>
<div class="lb-trans"><p>(TheNewswire)</p>
</div><p>Vancouver, British Columbia</p>
<div class="lb-trans"><p>加拿大不列颠哥伦比亚省温哥华</p>
</div><p>– TheNewswire -</p>
<div class="lb-trans"><p>– TheNewswire -</p>
</div><p>March 19, 2026 – MindBio</p>
<div class="lb-trans"><p>2026 年 3 月 19 日– MindBio</p>
</div><p>Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6);</p>
<div class="lb-trans"><p>Therapeutics Corp. (CSE: MBIO); (Frankfurt: WF6);</p>
</div><p>(OTCQB:MBQIF), (the “Company” or</p>
<div class="lb-trans"><p>(OTCQB:MBQIF)，(“公司” 或</p>
</div><p>“MindBio”), a biotechnology company commercializing AI-driven</p>
<div class="lb-trans"><p>“MindBio”) 是一家生物技术公司，专注于商业化基于人工智能的</p>
</div><p>voice analytics for drug and alcohol intoxication detection announces</p>
<div class="lb-trans"><p>语音分析技术，用于检测药物和酒精中毒，今天宣布</p>
</div><p>today that it is upsizing its non-brokered private placement (the</p>
<div class="lb-trans"><p>将其于 2026 年 2 月 18 日之前宣布的非承销私募融资（“融资”）</p>
</div><p>“Offering”) previously announced on February 18, 2026 from $650,000</p>
<div class="lb-trans"><p>从 65 万美元增加至最高 150 万美元，依据该融资，公司计划</p>
</div><p>to up to $1,500,000, pursuant to which the Company intends to now</p>
<div class="lb-trans"><p>现在发行最多 2,500,000 个单位（“单位”），每个单位的价格为</p>
</div><p>issue up to 2,500,000 units of the Company (the “Units”) at a price</p>
<div class="lb-trans"><p>0.60 美元，预计总收益最高可达 150 万美元。每个单位</p>
</div><p>of $0.60 per Unit for gross proceeds of up to $1,500,000. Each Unit</p>
<div class="lb-trans"><p>将由一股普通股（每股为 “股份”）和一个股份购买权证（每个为 “权证”）组成。每个权证将赋予持有人在融资结束后三十六个月内以</p>
</div><p>will consist of one common share of the Company (each, a</p>
<div class="lb-trans"><p>0.80 美元的价格购买额外股份的权利，若在此期间内，加拿大证券交易所的股份收盘价超过 1.00 美元，权证将提前到期。</p>
</div><p>“Share”) and one Share purchase warrant (each, a “Warrant”). Each</p>
<div class="lb-trans"><p>与融资完成相关，公司将向引荐订阅者的合格第三方支付介绍费。所有与融资相关发行的证券将根据适用的证券法，受到为期四个月零一天的转售限制。</p>
</div><p>Warrant will entitle the holder to acquire an additional Share at a</p>
<div class="lb-trans"><p>融资的完成仍需最终的董事会和监管机构批准。</p>
</div><p>price of $0.80 for a period of thirty-six months following closing of</p>
<div class="lb-trans"><p>如需更多信息，请联系：</p>
</div><p>the Offering, subject to accelerated expiry in the event the closing</p>
<div class="lb-trans"><p>Justin Hanka，首席执行官</p>
</div><p>price of the Shares on the Canadian Securities Exchange exceeds $1.00</p>
<div class="lb-trans"><p>+61 433140886</p>
</div><p>for ten consecutive trading days.</p>
<div class="lb-trans"><p>justin@mindbiotherapeutics.com</p>
</div><p>In connection with completion of the Offering, the</p>
<div class="lb-trans"><p>www.mindbiotherapeutics.com</p>
</div><p>Company will pay finders’ fees to eligible third-parties who have</p>
<div class="lb-trans"><p>关于 MindBio Therapeutics Corp.</p>
</div><p>introduced subscribers to the Offering. All securities issued in</p>
<div class="lb-trans"><p>MindBio 是一家生物技术公司，专注于通过语音分析商业化人工智能预测技术，用于检测药物和酒精中毒。该人工智能预测模型使用超过 5000 万个数据点，仅通过人声就能以显著的准确性预测酒精中毒。公司正在开发一个企业平台，包括集成定制硬件和软件的边缘人工智能终端，用于在包括矿业、航空、建筑和执法等多个企业环境中，利用人声和人工智能检测药物和酒精中毒。</p>
</div><p>connection with the Offering will be subject to restrictions on resale</p>
<div class="lb-trans"><p>关于前瞻性声明的警示说明：</p>
</div><p>for a period of four-months-and-one-day in accordance with applicable</p>
<div class="lb-trans"><p>本新闻稿包含适用证券法意义上的 “前瞻性声明”，包括但不限于公司完成融资的能力。前瞻性声明可以通过诸如：“预期”、“打算”、“计划”、“预算”、“相信”、“项目”、“估计”、“期望”、“安排”、“预测”、“战略”、“未来”、“可能”、“可能”、“将要”、“可以”、“应该”、“会” 等词语及类似的未来时期的参考或否定或可比术语，以及通常用于未来和条件的术语来识别。前瞻性声明基于提供时的假设。然而，不能保证这些假设将反映这些项目或因素的实际结果。</p>
</div><p>securities laws.</p>
<div class="lb-trans"><p>此外，还有已知和未知的风险因素可能导致公司的实际结果和财务状况与前瞻性声明中所指示的有重大差异。因此，您不应依赖这些前瞻性声明。可能导致实际结果和财务状况与前瞻性声明中所指示的有重大差异的重要风险因素包括但不限于：公司可能无法筹集融资的总收益；未能获得最终监管批准；以及在其企业平台的开发或部署中面临技术挑战；加拿大和澳大利亚的一般经济、市场和商业条件；市场波动；以及本新闻稿中描述的任何交易或事件的时间表出现意外延误。所有前瞻性信息均完全受此警示声明的限制。</p>
</div><p>Completion of the Offering remains subject to final</p>
<div class="lb-trans"><p>公司不承担修订或更新任何此类前瞻性声明的义务，也不承担公开宣布任何修订结果的义务，以反映未来的结果、事件或发展，除非法律要求。</p>
</div><p>board and regulatory approvals.</p>
<div class="lb-trans"><p>加拿大证券交易所及其监管服务提供者（根据加拿大证券交易所政策定义的术语）对本发布的充分性或准确性不承担任何责任。</p>
</div><p>For further information, please contact:</p>
<div class="lb-trans"><p>版权 (c) 2026 TheNewswire - 保留所有权利。</p>
</div><p>Justin Hanka, Chief Executive</p>
<p>Officer</p>
<p>+61 433140886</p>
<p>justin@mindbiotherapeutics.com</p>
<p>www.mindbiotherapeutics.com</p>
<p>About MindBio TherapeuticsCorp.</p>
<p>MindBio is a biotechnologycompany that is commercialising AI prediction technologies for drugand alcohol intoxication detection via voice analysis. The AIprediction model uses over 50 million data points to predict alcoholintoxication with remarkable accuracy, just by using the human voice.The Company is developing an enterprise platform including Edge-AIkiosks integrating bespoke hardware and software for the detection ofdrug and alcohol intoxication using the human voice and AI in a rangeof enterprise environments including the mining industry, aviation,construction and law enforcement.</p>
<p>Cautionary Note ConcerningForward-Looking Statements:</p>
<p>The press release contains“forward-looking statements” within the meaning of applicablesecurities laws, including but not limited to, the Company’s abilityto complete the Offering. Forward-looking statements can be identifiedby words such as: “anticipate,” “intend,” “plan,”“budget,” “believe,” “project,” “estimate,”“expect,” “scheduled,” “forecast,” “strategy,”“future,” “likely,” “may,” “to be,” “could,”“would,” “should,” “will” and similar references to futureperiods or the negative or comparable terminology, as well as termsusually used in the future and conditional. Forward-looking statementsare based on assumptions as of the date they are provided. However,there can be no assurance that such assumptions will reflect theactual outcome of such items or factors.</p>
<p>Additionally, there are known andunknown risk factors that could cause the Company’s actual resultsand financial conditions to differ materially from those indicated inthe forward-looking statements. Therefore, you should not rely on anyof these forward-looking statements. Important risk factors that couldcause actual results and financial conditions to differ materiallyfrom those indicated in the forward-looking statements, include amongothers: the risk that the Company may not be able to raise the grossproceeds of the Offering; the failure to obtain the final regulatoryapproval; and technical challenges in the development or deployment ofits enterprise platform; general economic, market and business conditions in Canada andAustralia; market volatility; and unforeseen delays in timelines forany of the transactions or events described in this press release. All forward-looking information is qualified in its entirety by thiscautionary statement.</p>
<p>The Company disclaims any obligationto revise or update any such forward-looking statement or to publiclyannounce the result of any revisions to any of the forward-lookinginformation contained herein to reflect future results, events ordevelopments, except as required by law.</p>
<p>Neither the Canadian SecuritiesExchange nor its Regulation Service Provider (as that term is definedin the policies of the Canadian Securities Exchange) acceptsresponsibility for the adequacy or accuracy of this release.</p>
<p>Copyright (c) 2026 TheNewswire - All rights reserved.</p>

MindBio Announces Upsize to Private Placement up to $1.5 Million

The newswire.ca

Invesco Nasdaq Biotechnology ETF

基因改革 ETF - ARK

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 ETF - SPDR

医疗业 ETF - Vanguard

2 倍做空纳斯达克生物技术 ETF - ProShares

医药突破 ETF - ALPS

生物科技 ETF - VanEck Vectors

动态生物技术与基因组 ETF - Invesco

标普生物技术 3 倍做多 - Direxion

MindBio 宣布将私人配售规模扩大至最高 150 万美元